Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- In Q2, Drug Companies Lobbied to Expand Many Government Healthcare Programs
- A look at what drug companies spent on lobbying in the second quarter of 2009 shows an interesting dichotomoy: It's a parade of selfishness that, if successful, may end up doing more to expand government-run healthcare in the U.S. than President Obama's reforms. by Jim Edwards
- Blog posts 2009-09-01
- Is There Really a "Market Price" for Drugs?
- Everyone seems to be ganging up on high drug prices these days. In two separate hearings last week, Congressional committees took after drugmakers for big markups on specialty treatments and a pharma "windfall" created by the Medicare prescription-drug benefit, while the WSJ took a hard look at the opacity of...
- Blog posts 2008-07-27
- Oxymoron No More: The Potential of Nonprofit Drug Companies to Deliver on the Promise of Medicines for the Developing World
- Although some pharmaceutical company efforts to develop and distribute drugs in developing countries have been successful, many fall short of meeting needs in resource-poor nations. The paper discusses the concept of a nonprofit pharmaceutical company dedicated to developing and distributing drugs for diseases endemic in developing countries. Using the experience...
- White papers 2005-08-01
- Drug Companies' Health Education Campaigns No Longer Speak Spanish
- For the first time in at least three years, drug companies have spent zero dollars on Spanish-language television for their unbranded health education ads, Nielsen-Monitor Plus reports. The wholescale write-off of Hispanic TV draws attention to how little Spanish-language provision there is in drug marketing. Of the...
- Blog posts 2008-10-03
- NEJM: Foreign Drug Trials Could Hurt U.S. Patients
- The increasing use of foreign drug trials may hurt U.S. patients because of genetic and environmental differences in overseas study subjects, a new study in the New England Journal of Medicine suggests. "Are trial results accurate and valid, and can they be extrapolated to other settings?" asks a team from...
- Blog posts 2009-02-19
- Drug Makers Gave Lobbyists an Xmas Gift -- Millions More to Lobby Obama Administration
- A New Year will bring a new president, a new FDA chief, many new drug regulations, and, possibly, health insurance reform. Mindful of the ton of major drug brands that will go off-patent in 2009, drug companies have not rested in their lobbying efforts over generics and patent issues. They...
- Blog posts 2008-12-31
Additional Resources
- Cholestech Corporation Announces Nationwide Pharmacy Distribution Agreement With Bergen Brunswig Drug Company
- HAYWARD, Calif.--BW HealthWire--July 27, 1998--Cholestech Corporation (NASDAQ:CTEC) today announced the signing of a non-exclusive, multi-year distribution agreement with a subsidiary of Bergen Brunswig Drug Company (NYSE:BBC) to market the Cholestech L.D.XR System to pharmacies nationwide. Bergen Brunswig is one of the nation's leading suppliers of pharmaceuticals and medical-surgical products."We are...
- Research articles 1998-07-27
- Xencor Completes $45 Million Financing with MedImmune Ventures, Novo Nordisk and HealthCare Ventures
- MONROVIA, Calif. -- Xencor, a company developing protein and antibody therapeutics, today announced that it raised $45 million in a private financing led by MedImmune Ventures, Inc., and including new investors Novo Nordisk and HealthCare Ventures as well as existing investor Zen Investments. The financing, which includes an initial $6...
- Research articles 2006-10-19
- Research and Markets: Discover What Makes AmerisourceBergen/PharMerica One of the Leading Drug Distributors and Institutional Pharmacy Providers in the Country
- DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c31438) has announced the addition of AmerisourceBergen/PharMerica Business Intelligence Report to their offering. AmerisourceBergen Corporation AmerisourceBergen is one of the largest pharmaceutical services companies in the United States. Servicing both pharmaceutical manufacturers and healthcare providers in the pharmaceutical supply channel, the company provides...
- Research articles 2006-01-24
- How Healthcare Gets Sold To Patients, Courtesy of Omnicom
- Given the changes sweeping through healthcare these days, it's not surprising that companies in the industry might want to update their marketing strategies from time to time. Watching that particular sausage get made isn't always pretty, but it can be instructive. Take, for instance, Thursday's announcement from...
- Blog posts 2008-06-15
- Lilly, Barr, AZ and Sepracor Were Generous to Sen. Hatch's Utah Charity
- Five drug and device companies, plus their lobbyist, PhRMA, are all very, very concerned about the welfare of Utah families. So concerned they gave $172,400 to the Utah Family Foundation over the last few years. By amazing coincidence, the foundation was founded by Sen. Orrin Hatch, who...
- Blog posts 2009-03-02
- Roche Fraud Case Exposes Corruption Encouraged by Drug Pricing Politics
- Roche has emerged as both victim and enabler in a big corruption case whose basis was the arcane pricing policies of U.S. drugs. In the case, two brothers who ran a medical supplies company were sentenced to nine years in prison for skimming contracts and avoiding taxes. ...
- Blog posts 2009-01-15
- FDA to Allow "Off-Label" Unapproved Drug Promotion
- The FDA has "finalized" guidelines allowing drug companies to promote drugs for unapproved ("off-label") uses. The guidelines will allow companies to distribute peer-reviewed scientific literature discussing off-label uses. Drug companies and their right-wing stalking horse, the Washington Legal Foundation, have been pushing for this move for years....
- Blog posts 2009-01-13
- J&J and Risperdal: New Claims of Kickbacks and Fraudulent Marketing
- The news on Risperdal continues to get worse for Johnson & Johnson and its antipsychotic unit, Janssen Pharmaceuticals. Texas officials filed suit against the company alleging Medicaid fraud, kickbacks and improper marketing of the drug to children and the poor in that state. J&J denies the claims. ...
- Blog posts 2008-12-17
- Man Bites Dog: Former Merck CEO Blasts High Drug Prices
- Most pharmaceutical companies insist that high drug prices are a natural consequence of the risky business of drug discovery, and that huge profits on marketed drugs are necessary to cover the costs of the 5,000 to 10,000 experimental drugs that fail for every one that succeeds. In fact, there are...
- Blog posts 2008-05-05
- Healthcare Roundup: No HLTH-WebMD Merger, Higher Medicaid Spending, Mental-Health Parity, and More
- HLTH, WebMD call off merger -- HLTH, a holding company that currently owns 84 percent of the publicly traded WebMD, pulled the plug on a proposed merger with that subsidiary. The companies cited financial-market uncertainty and difficulty finding a buyer for a second HLTH unit, Porex, which makes plastic products...
- Blog posts 2008-10-20
- FDA to Allow "Off-Label" Unapproved Drug Promotion
- The FDA has "finalized" guidelines allowing drug companies to promote drugs for unapproved ("off-label") uses. The guidelines will allow companies to distribute peer-reviewed scientific literature discussing off-label uses. Drug companies and their right-wing stalking horse, the Washington Legal Foundation, have been pushing for this move for years. They regard drug...
- News items 2009-08-07
- Walgreen Profit Misses View and CVS Stands By Outlook
- By Jessica Wohl CHICAGO (Reuters) - Walgreen Co WAG posted a smaller-than-expected quarterly profit and again cut its store opening plans, showing that after years of rapid growth, drugstores are being hit by the recession. Rival CVS Caremark Corp CVS also said it is seeing consumers cut back. CVS, which...
- News items 2009-08-07
- Altamonte Springs, Fla.-Based Drug Distributor to Buy Back Stock.
- Knight Ridder/Tribune Business News Aug. 25 -- Priority Healthcare Corp. said Tuesday that it plans to buy back as many as 2 million shares of common stock -- almost as many as the company sold in a secondary offering two months ago. ...
- Research articles 1999-08-25
- Neurogen Corporation Announces Webcast of November 14 Presentation at Credit Suisse Healthcare Conference
- BRANFORD, Conn. -- Neurogen Corporation (Nasdaq: NRGN), a drug discovery and development company, announced today that William H. Koster, CEO, will present a Company overview at the Credit Suisse 2007 Annual Healthcare Conference on Wednesday, November 14 at 4:30 p.m. MST/6:30 p.m. EST.
- Research articles 2007-11-07
- << Previous
- page 1 of 1
- Next >>
